AI chatbot aims to curb drinking in liver disease patients
NCT ID NCT07450144
First seen Mar 06, 2026 · Last updated May 01, 2026 · Updated 10 times
Summary
This pilot study tests whether a chatbot powered by large language models can help people with metabolic alcohol-related liver disease (MetALD) reduce their alcohol intake. Researchers will enroll 50 adults in Hong Kong to see if the chatbot is easy to use and if participants stick with it for 3 to 6 months. The goal is to gather early data on feasibility and effectiveness before a larger trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hong Kong Queen Mary Hospital
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.